News & Updates

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024 bySarah Cheung

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

 

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024
Rectal spacers in MR-guided SBRT for localized prostate cancer very well tolerated, improve rectal sparing and target coverag
Rectal spacers in MR-guided SBRT for localized prostate cancer very well tolerated, improve rectal sparing and target coverage
20 Mar 2024
Bright light therapy of no benefit in teens with moderate or severe depression
Bright light therapy of no benefit in teens with moderate or severe depression
19 Mar 2024

In the treatment of adolescents with moderate or severe major depressive disorder, adding bright light therapy to psychiatric inpatient treatment as usual falls short of significantly reducing depressive symptoms when compared with placebo, as shown in a study.

Bright light therapy of no benefit in teens with moderate or severe depression
19 Mar 2024